PUBLISHER: The Business Research Company | PRODUCT CODE: 1946605
PUBLISHER: The Business Research Company | PRODUCT CODE: 1946605
Next-generation sequencing is a sequencing technology that provides ultra-high throughput, scalability, and speed, and is utilized to determine the genetic variation associated with diseases or other biological phenomena.
The primary products in the next-generation sequencing market include NextSeq systems, MiniSeq systems, NovaSeq systems, iSeq 100 systems, ion PGM Systems, Ion Proton systems, ion GeneStudio S5 systems, PacBio RS II Systems, Sequel systems, and others. The MiniSeq system combines load-and-go operation with an intuitive user interface for a fast and easy NGS workflow. It integrates clonal amplification, sequencing through synthesis, and base calling into a single benchtop instrument, eliminating the need for additional equipment. Various technologies in next-generation sequencing include sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, nanopore sequencing, and other sequencing technologies applied in diagnostics, drug discovery, and other applications.
Tariffs are influencing the next generation sequencing market by increasing costs of imported sequencing instruments, reagents, flow cells, and analytical software components. Research institutions and diagnostic laboratories in North America and Europe are most affected due to dependence on imported high-end sequencing platforms, while Asia-Pacific faces cost pressures on reagent manufacturing and exports. These tariffs are increasing operational costs and slowing equipment upgrades. At the same time, they are encouraging regional reagent production, localized instrument assembly, and greater investment in domestic genomics infrastructure.
The next generation sequencing market research report is one of a series of new reports from The Business Research Company that provides next generation sequencing market statistics, including next generation sequencing industry global market size, regional shares, competitors with a next generation sequencing market share, detailed next generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the next generation sequencing industry. This next generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The next generation sequencing market size has grown rapidly in recent years. It will grow from $14.2 billion in 2025 to $16.31 billion in 2026 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to increasing research activity in genomics, declining costs of sequencing technologies, expansion of molecular diagnostics laboratories, rising demand for disease-associated genetic analysis, availability of advanced sequencing reagents.
The next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $28.59 billion in 2030 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to increasing adoption of precision medicine initiatives, rising investments in population genomics studies, expansion of NGS in oncology diagnostics, growing demand for rapid sequencing solutions, increasing integration of sequencing data with clinical decision systems. Major trends in the forecast period include increasing adoption of high-throughput sequencing platforms, rising demand for clinical diagnostic sequencing, growing integration of ai-based bioinformatics tools, expansion of targeted and personalized medicine applications, enhanced focus on cost-effective sequencing workflows.
The rising demand for personalized medicine is anticipated to drive the expansion of the next-generation sequencing market in the coming years. Personalized medicine, also referred to as precision medicine, represents an innovative approach to healthcare and treatment that considers an individual's distinct genetic, environmental, and lifestyle characteristics to customize medical decisions and therapies. Next-generation sequencing serves as a core technology in personalized medicine, enabling accurate analysis of a person's genetic profile and the creation of tailored healthcare plans. For example, in February 2024, the Personalised Medicine Coalition, a US-based hospital and healthcare organization, reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, compared to six approvals in 2022. Consequently, the growing demand for personalized medicine is fueling the growth of the next-generation sequencing market.
Major companies in the next-generation sequencing market are concentrating on developing advanced technologies such as hybrid long- and short-read sequencing to improve genomic resolution and accuracy. Hybrid long- and short-read sequencing integrates the high throughput and low error rates of short reads with the structural insights and coverage advantages of long reads. For example, in March 2023, Illumina, a US-based biotechnology firm, introduced the Illumina Complete Long Read Prep, Human assay, featuring its innovative Complete Long Read technology. The assay allows both long- and short-read data to be generated on the same Illumina instrument and is fully compatible with NovaSeq X Plus, NovaSeq X, and NovaSeq 6000 systems. Its primary features include a simplified workflow with significantly lower DNA input requirements compared to other long-read platforms, integration of Illumina sequencing-by-synthesis (SBS) chemistry with DRAGEN secondary analysis for highly accurate whole-genome sequencing, access to difficult-to-map and complex genic regions, and a promotional cost of US $1,350 per genome (on NovaSeq X Plus with a 25B flow cell), covering long- and short-read library prep, sequencing, and cloud analysis.
In September 2025, SeqOne, a France-based provider of AI-powered genomic analysis platforms, acquired Congenica for an undisclosed sum. With this acquisition, SeqOne intends to combine its AI-driven Next-Generation Sequencing (NGS) capabilities with Congenica's clinical decision support and genomic interpretation technologies, enhancing its global position in AI-powered genomic medicine and speeding up the delivery of accurate, personalized diagnostics. Congenica is a UK-based digital health company that provides clinical decision-support solutions and genomic interpretation services to hospitals and research organizations worldwide.
Major companies operating in the next generation sequencing market are Illumina Inc, Thermo Fisher Scientific Inc, Pacific Biosciences of California Inc, Oxford Nanopore Technologies Ltd, QIAGEN NV, Agilent Technologies Inc, PerkinElmer Inc, BGI Group, 10x Genomics Inc, Takara Bio Inc, New England Biolabs Inc, Twist Bioscience Corp, Element Biosciences Inc, Ultima Genomics Inc, SeqWell Inc, Integrated DNA Technologies Inc, LGC Limited, Bio-Rad Laboratories Inc, Zymo Research Corporation, NimaGen BV
North America was the largest region in the next generation sequencing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next generation sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the next generation sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The next generation sequencing market consist of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductor sequencing, nano-pore sequencing, single-molecule real-time sequencing, and other technologies that are used for next generation sequencing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Next Generation Sequencing Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses next generation sequencing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for next generation sequencing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The next generation sequencing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.